JOURNAL ARTICLE

Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial

Gudmundur Johannsson, Murray B Gordon, Michael Højby Rasmussen, Ida Holme Håkonsson, Wolfram Karges, Claus Sværke, Shigeyuki Tahara, Koji Takano, Beverly M K Biller
Journal of Clinical Endocrinology and Metabolism 2020 February 5
32022863

CONTEXT: Growth hormone (GH) replacement requires daily GH injections, which is burdensome for some adult patients with GH deficiency (AGHD).

OBJECTIVE: To demonstrate efficacy and safety of somapacitan, a once-weekly reversible albumin-binding GH derivative, versus placebo in AGHD.

DESIGN: Randomized, parallel-group, placebo-controlled (double-blind) and active-controlled (open-label) Phase 3 trial, REAL 1 (NCT02229851).

SETTING: Clinics in 17 countries.

PATIENTS: Treatment-naïve patients with AGHD (n=301 main period, 272 extension period); 257 patients completed the trial.

INTERVENTIONS: Patients were randomized 2:2:1 to once-weekly somapacitan, daily GH, or once-weekly placebo for 34 weeks (main period). During the 52-week extension period, patients continued treatment with somapacitan or daily GH.

MAIN OUTCOME MEASURES: Body composition measured using dual-energy X-ray absorptiometry (DXA). Primary endpoint was change to week 34 in truncal fat percentage. IGF-I SDS values were used to dose titrate.

RESULTS: At 34 weeks, somapacitan significantly reduced truncal fat percentage (estimated difference: -1.53% [-2.68; -0.38]; p=0.0090), demonstrating superiority compared with placebo and improved other body composition parameters (including visceral fat and lean body mass) and IGF-I SDS. At 86 weeks, improvements were maintained with both somapacitan and daily GH. Somapacitan was well tolerated, with similar adverse events (including injection-site reactions) compared with daily GH.

CONCLUSIONS: In AGHD patients somapacitan administered once-weekly demonstrated superiority over placebo, and overall treatment effects and safety of somapacitan were in accordance with known effects and safety of GH replacement for up to 86 weeks of treatment. Somapacitan may provide an effective alternative to daily GH in AGHD.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
32022863
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.